Verition Fund Management’s Ascendis Pharma A/S ASND Stock Holding History

Verition Fund Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-7,420	Closed	-$1.58M	–	2307
2025 Q4	$1.58M	Buy	+7,420	New	+$1.53M	0.01%	1808
2025 Q3	–	Sell	-15,324	Closed	-$2.64M	–	3746
2025 Q2	$2.64M	Buy	+15,324	New	+$2.5M	0.01%	1719
2025 Q1	–	Sell	-4,300	Closed	-$592K	–	3320
2024 Q4	$592K	Buy	+4,300	New	+$565K	﹤0.01%	2373
2023 Q4	–	Sell	-87,112	Closed	-$8.16M	–	2331
2023 Q3	$8.16M	Sell	87,112 -22,946	-21%	-$2.15M	0.1%	277
2023 Q2	$9.82M	Buy	+110,058	New	+$9.58M	0.13%	204

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Verition Fund Management's ASND Position: Q1 2026 in Review

Verition Fund Management sold out of Ascendis Pharma A/S (ASND) in Q1 2026, closing a stake of 7,420 shares — an estimated $1.58M sold.

Verition Fund Management first reported a position in ASND in Q2 2023 and held it in 5 quarters. The position peaked at $9.82M in Q2 2023. 274 funds tracked by Wall St. Rank hold ASND as of Q1 2026.

Verition Fund Management reported no remaining Ascendis Pharma A/S position as of Q1 2026 after selling out during the quarter.
Verition Fund Management sold 7,420 Ascendis Pharma A/S shares in Q1 2026, an estimated $1.58M.
Verition Fund Management first reported a position in Ascendis Pharma A/S in Q2 2023 and held it in 5 quarters.
Verition Fund Management's Ascendis Pharma A/S position peaked at $9.82M in Q2 2023.
274 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q1 2026.

Based on Verition Fund Management's 13F filing for Q1 2026, filed 15 May 2026.